In conclusion, targeting the PDGF-B/PDGFRβ axis in combination with VEGF inhibitors may offer a novel therapeutic approach for managing resistance to conventional anti-angiogenic therapies in RCC. Here, VEGFA is linked to renal cell carcinoma.